A nonprofit working to reduce the burden of
#asthma
worldwide through publications such as evidence-based guidelines and events such as
#WorldAsthmaDay
.
GINA UPDATE: an update of the GINA 2024 report was published on 22 May 2024, as we became aware that some medication doses for anti-inflammatory reliever therapy in Box 4-8 were being misread. Download the latest version from . Please share.
Today is World Asthma Day! GINA emphasizes the need to empower people with asthma with the appropriate education to manage their disease - Asthma Education Empowers.
Download the new 2024 report here:
#WorldAsthmaDay
#GINA
#Asthma
#AsthmaEducation
GINA 2024 key changes, based on evidence (where available) and consensus, include recommendations on the choice of initial treatment step for adults and adolescents. The GINA cycle of asthma management - asthma treatment is not just about medications.
Today is World Asthma Day!
GINA is working to improve the lives of people with asthma globally - Asthma Care for All.
Download the new 2023 report here:
#WorldAsthmaDay
#GINA
#Asthma
The 2024 GINA diagnostic flowchart for clinical practice has been revised. Many health professionals don’t have access (or timely access) to spirometry. While less reliable than spirometry peak expiratory flow is better than relying on symptoms alone.
GINA 2024 provides recommendations about cough variant asthma which may be difficult to distinguish from other causes of chronic cough, since spirometry may be normal - treatment is the same as for asthma in general, with ICS-containing treatment. See
Please share this week 5 message from GINA: Confirm the diagnosis of asthma in adults and children before starting controller treatment wherever possible, as it is often more difficult afterwards.
GINA is happy to announce the 2023 Pocket Guide is now available online! Visit our website to download the updated GINA 2023 Pocket Guide today.
#GINA
#ASTHMA
Track 1 the preferred GINA approach reduces the risk of severe asthma exacerbations, compared with using a SABA reliever while achieving similar symptom control, similar lung function, and a lower oral corticosteroid burden.
GINA is excited to announce the 2022 Pocket Guide is now available online! Visit our website to download the updated GINA 2022 Pocket Guide today!
#GINA
#ASTHMA
Please share. In children 5 years and younger, asthma is more likely if they have wheezing or coughing with exercise/laughing/crying or outside of respiratory infections, and if they have a history of eczema or allergic rhinitis. &
Please retweet: Evidence based Global Initiative on
#Asthma
(GINA) 2021 update now available. New Two-Track approach for Adults and Adolescents.
@bigcatdoc
see
There is strong evidence for prescribing combination inhaled corticosteroid-formoterol in one inhaler for relief of asthma symptoms in adults/adolescents. It reduces severe asthma attacks & emergency visits. Short-acting beta2-agonist relievers do
Confirming asthma diagnosis once inhaled corticosteroids (ICS) are started can be difficult. If asthma is well-controlled, stepping down ICS may help with diagnosis. Start with assessment – see highlighted section GINA 2024 Box 1-5. Full explanation at
Stepping down
#Asthma
treatment: Once asthma is well controlled for 2–3 months, consider stepping down gradually to find the minimum effective dose, monitoring the patient frequently. Step up again if needed. Box 3-7 GINA 2022 ).
Please share: Asthma management should be personalized and adjusted in a continual cycle of assessment, treatment and review, to minimize symptoms and prevent exacerbations.
@GARDbreathe
see &
GINA has updated its interim guidance about COVID-19 and asthma, including new advice about COVID-19 vaccines.
Visit to view & download the updated information.
An asthma attack is a signal that something went wrong! -1:
Is the person prescribed an inhaled corticosteroid? If not, why not? GINA recommends that everyone with asthma should be prescribed an ICS, either regularly, or with as-needed ICS-formoterol.
Please share this week six message from
#GINA
:
#Asthma
management is not “one-size-fits-all.” It includes treatment of modifiable risk factors & comorbidities, nonpharmacological strategies, & medication, education, adherence & inhaler technique. See
Please share: Inhaled Corticosteroid (ICS) -containing treatment is recommended for all children 6–11 years with asthma: either regularly or, in mild asthma, by taking ICS whenever SABA is taken.
Please share this week 39 message on
#asthma
from GINA: For safety in Step 1, taking Inhaled corticosteroid (ICS) whenever SABA is taken is preferable to taking SABA alone.
GINA 2024 clarifies that assessment of symptom control should not be limited to the last 4 weeks, and emphasizes that assessing symptom control is not enough. Risk factors for exacerbations, including past exacerbations, must also be assessed.
Please share this week 36 message from
#GINA
. The reason for preferring as-needed-only ICS–formoterol over as-needed SABA (alone or with daily ICS) in Steps 1 &2: patients with “mild” asthma can have severe exacerbations. See
#GINA
2023 Updated Recommendation: In children 6–11 years with asthma symptoms less than twice a month & no exacerbation risk factors (Box 2-2b below) the preferred initial treatment is ICS taken whenever SABA is taken.
An asthma attack is a signal that something went wrong! 3 of 4: Was a post-attack review done? GINA recommends an assessment within a week to identify and fix modifiable risk factors such as undertreatment with inhaled corticosteroids.
2022 evidence based GINA reports published on World Asthma Day: 96% of all asthma deaths occur in low or middle income countries. There is an urgent need to ensure access to affordable, quality-assured inhaled asthma medications for all people with asthma.
Please share this week 8 message from GINA on
#asthma
Inhaled Corticosteroid (ICS) -containing treatment is recommended for all children 6–11 years with asthma: either regularly or, in mild asthma, by taking ICS whenever SABA is taken.
#Asthma
in adults, adolescents and children 6–11 years should not be managed with short-acting β2-agonist relievers (SABAs) alone. Inhaled corticosteroid (ICS)-containing therapy reduces the risk of severe exacerbations, and controls symptoms. See
reason for preferring as-needed-only ICS–formoterol over as-needed SABA (alone or with daily ICS) in Steps 1&2 in adults & adolescents,and for recommending ICS whenever SABA reliever is taken in step 1 in children ≤12: patients with “mild”
#asthma
can have severe exacerbations.
Please share this week 7 ‘bite sized’ message from GINA:
#Asthma
in adults and adolescents should not be managed solely with short-acting β2-agonist relievers (SABAs). See
Please share this Week 8 GINA tweet: Inhaled Corticosteroid (ICS) -containing treatment is recommended for all children 6–11 years with asthma: either regularly or, in mild asthma, by taking ICS whenever SABA is taken. See &
World Asthma Day - May 5, 2021
This year’s theme is “Uncovering Asthma Misconceptions”. The theme provides a call to action to address common widely held myths and misconceptions concerning asthma.
#WorldAsthmaDay
For more visit
Please share this recommendation from GINA: Adults and adolescents with
#MILD
#asthma
should be treated with inhaled corticosteroid (ICS) containing therapy either regularly every day or with low-dose ICS–formoterol taken as needed for symptom relief. See
GINA is happy to announce the 2022 Pocket Guide is now available in Spanish! Visit our website to download the 2022 Spanish Pocket Guide today!
#ASTHMA
#GINA
World Asthma Day theme 2021 is “Uncovering Asthma Misconceptions”. Video responses from colleagues world wide have been compiled- watch this and share:
An asthma attack is a signal that something went wrong! 2 of 4:
Was a post-attack review done? GINA recommends an assessment within a week to identify and fix modifiable risk factors such as poor inhaler technique.
Please Share: Confirm the diagnosis of
#asthma
in adults and older children before starting controller treatment, whenever possible, as it is often more difficult afterwards see GINA exec summary at
Week 37 message from GINA:
Before considering an
#Asthma
regimen with a SABA reliever, consider whether the patient is likely to adhere to controller therapy. If not then advise use of Inhaled corticosteroid as needed together with the reliever.
Track 1 the preferred GINA approach reduces the risk of severe asthma exacerbations compared with using a SABA reliever while achieving similar symptom control, similar lung function, and a lower oral corticosteroid burden.
See
Asthma management is not “one-size-fits-all.” It includes identification & treatment of modifiable risk factors and comorbidities, nonpharmacological strategies & education and skills training particularly inhaler technique and adherence.
The goal of asthma treatment should be personalized for each patient, aiming for the patient’s best possible long-term outcomes. This includes both long-term symptom control and long-term risk reduction. Assessing recent symptom control is not enough.
Please share:In children 5 years and younger, asthma is more likely if they have wheezing or coughing with exercise/laughing/crying or outside of respiratory infections, and if they have a history of eczema or allergic rhinitis. See the GINA resources at
The GINA Severe asthma printed booklet is now available to purchase on Amazon at : please share with anyone treating asthma - it’s really important to identify and refer anyone with possible severe asthma.
Week 11 (9)
GINA asthma adult and adolescent treatment is divided into two tracks, based on inhaled reliever medication. Track 1 is recommended by GINA because it reduces the risk of severe asthma exacerbations compared with using a SABA reliever. See
Today is World Asthma Day!
GINA is working to improve the lives of people with asthma globally - Asthma Care for All.
Download the new 2023 report here:
#WorldAsthmaDay
#GINA
#Asthma
Week 10:In Steps 1&2, as-needed-only ICS-formoterol is preferred over as-needed SABA (alone or with daily ICS) because patients with so-called “mild” asthma can have severe exacerbations. See &
Before stepping up asthma treatment,confirm symptoms are due to asthma,identify and address modifiable risk factors (including incorrect inhaler technique,poor medication adherence,environmental exposures, and multimorbidity),and provide patient education.
World Asthma Day - May 2, 2023.
The Asthma care for All message promotes the development and implementation of effective asthma management programs in all resource countries.
#WorldAsthmaDay
#GINA
For more information:
Adults and adolescents with
#MILD
#asthma
should be treated with Inhaled Corticosteroid (ICS) containing therapy either regularly every day or with ICS–formoterol taken as needed for symptom relief.
In children 5 years and younger, asthma is more likely if they have wheezing or coughing with exercise/laughing/crying or outside of respiratory infections, and if they have a history of eczema or allergic rhinitis. See the GINA resources at
#Asthma
in adults and adolescents should not be managed solely with short-acting β2-agonist relievers(SABAs). See & and direct link to the GINA Reports is at 1/2
World Lung Day 2023
Let's raise awareness of the importance of lung health and ensure that everyone has access to the care they need.
More information:
#LeaveNoOneBehind
#GINA
#WorldLungDay
Today is World Asthma Day! Closing Gaps In Asthma Care has always been a mission for GINA. Download the new 2022 GINA report here:
#WorldAsthmaDay
#GINA
GINA asthma adult and adolescent treatment is divided into two tracks, based on inhaled reliever medication. Track 1 is the approach recommended by GINA because it reduces the risk of severe asthma exacerbations compared with using a SABA reliever.
World Asthma Day - May 7, 2024
Asthma Education Empowers. GINA emphasizes the need to empower people with asthma with the appropriate education to manage their disease, and to recognize when to seek medical help.
#WorldAsthmaDay
#GINA
Visit:
Week 37 message from GINA: Reason for preferring as-needed-only ICS–formoterol over as-needed SABA (alone or with daily ICS) in Steps 1 &2: adherence with daily ICS is often poor in patients with mild or infrequent symptoms, increasing risk of attacks.
Please share this week 16
#GINA
recommendation Before stepping up treatment to control symptoms or prevent exacerbations, confirm that asthma diagnosis, identify & address modifiable risk factors and provide patient education. See
Week 13 recommendation: Before considering an
#Asthma
regimen with a SABA reliever, consider whether the patient is likely to adhere to controller therapy. If not, Track 1 is preferred, to avoid SABA-only treatment.
World Asthma Day - May 3, 2022
This year’s theme is “Closing Gaps is Asthma Care”. There are a number of gaps in asthma care which require intervention in order to reduce preventable suffering.
#WorldAsthmaDay
#GINA
For more information visit
#ERSCongress
#ERSCongress2020
Prof Guy Brusselle emphasises the value of following
#GINA
#asthma
recommendations to reduce risk of poor outcome due to COVID-19. Aim for optimal control - ICS use is crucial - and avoid attacks (so that OCS are not needed ).
In a GINA
#asthma
meeting Dr Guy Brusselle highlights - well treated asthma does not pose a risk for severe COVID-19. however recent use of Oral Corticosteroids DOES pose a risk. So maintaining asthma control with treatment and preventing attacks is vital.
Week 1 ‘bite sized message’ from GINA: it is important for patients to be provided with education and skills in order to effectively manage their asthma. This includes prescribing the most appropriate inhaler device/drug combination for the patient. See
GINA asthma adult and adolescent treatment is divided into two tracks. Track 1, with ICS-formoterol reliever, is recommended by GINA because it reduces the risk of severe asthma exacerbations compared with using a SABA reliever and is simpler. See
Before stepping up treatment,confirm symptoms are due to asthma,identify and address modifiable risk factors (including incorrect inhaler technique,poor medication adherence, environmental exposures, and multimorbidity),and provide patient education.
An asthma attack is a signal that something went wrong! 1 of 4: Is the person prescribed an inhaled corticosteroid? If not, why not? GINA recommends that everyone with asthma should be prescribed an ICS, either regularly, or with as-needed ICS-formoterol.
An asthma attack is a signal that something went wrong! -1:
Is the person prescribed an inhaled corticosteroid? If not, why not? GINA recommends that everyone with asthma should be prescribed an ICS, either regularly, or with as-needed ICS-formoterol.
Save the Date!
Join world-renowned experts for the FIRs/GINA global update on asthma: the global burden, access and affordability, and the GINA 2023 strategy.
15 May 2023 16:00 CET
Register here:
#GINA
#Asthma
Before stepping up treatment to control symptoms or prevent exacerbations, confirm that asthma diagnosis, identify & address modifiable risk factor (see table), and provide patient education.
As part of supported asthma self-management, provide a personalized written asthma action plan for all patients, tailored to their health literacy, so they know how to recognize and respond to worsening asthma. An example of a plan is shown below.
Asthma management is not “one-size-fits-all.” It includes identification & treatment of modifiable risk factors and comorbidities, nonpharmacological strategies & education and skills training particularly inhaler technique and adherence.
GINA recommends assessing asthma control in two domains:
They are symptom control and risk factors for future attacks, including having had an attack in the previous year. It’s not enough to only ask about recent symptom control.
GINA recommends regularly assessing multimorbidity in people with asthma. Conditions such as rhinitis, sinusitis, gastro-oesophageal reflux, obesity, obstructive sleep apnoea, depression and anxiety, if not treated, can contribute to poor asthma control.
Track 1 the preferred GINA approach reduces the risk of severe asthma exacerbations, compared with using a SABA reliever while achieving similar symptom control, similar lung function, and a lower oral corticosteroid burden.
GINA 2024 Risks of LTRA’s - risk of neuropsychiatric adverse events: A reminder to advise patients/parents/caregivers about risks including new-onset nightmares and behavioral problems and, in some cases, suicidal ideation.
GINA is happy to announce the 2023 Pocket Guide is now available online! Visit our website to download the updated GINA 2023 Pocket Guide today.
#GINA
#ASTHMA
Today on World COPD Day,
@GOLD_COPD
aims to raise awareness for contributing factors to COPD during all stages of life & what we can do to promote lifelong lung health as well as protect vulnerable populations. Read more:
#WorldCOPDDay
#GOLD
#GINA